Wells Fargo & Co Reiterates “Buy” Rating for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating restated by analysts at Wells Fargo & Co in a research report issued on Wednesday.

Several other brokerages also recently weighed in on JAZZ. Morgan Stanley downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $183.00 target price for the company. in a research note on Wednesday, July 11th. Stifel Nicolaus increased their target price on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Finally, Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $191.94.

Shares of JAZZ traded up $5.80 during mid-day trading on Wednesday, hitting $147.99. 408,238 shares of the company’s stock were exchanged, compared to its average volume of 498,152. Jazz Pharmaceuticals has a fifty-two week low of $130.15 and a fifty-two week high of $184.00. The company has a market capitalization of $9.93 billion, a price-to-earnings ratio of 15.48, a price-to-earnings-growth ratio of 0.89 and a beta of 1.06. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.62 and a current ratio of 3.76.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping the consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 25.44%. The business had revenue of $469.37 million during the quarter, compared to the consensus estimate of $482.64 million. During the same quarter in the prior year, the firm earned $3.22 earnings per share. The business’s quarterly revenue was up 14.0% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals will post 11.71 EPS for the current year.

In related news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $175.70, for a total value of $35,140.00. Following the completion of the transaction, the executive vice president now directly owns 25,572 shares of the company’s stock, valued at $4,493,000.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick G. Enright sold 10,130 shares of the firm’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $168.76, for a total transaction of $1,709,538.80. Following the completion of the transaction, the director now directly owns 19,884 shares of the company’s stock, valued at $3,355,623.84. The disclosure for this sale can be found here. Insiders sold 16,730 shares of company stock worth $2,796,532 over the last quarter. 3.90% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at $106,000. Tiverton Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $198,000. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $204,000. FDx Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $244,000. Finally, Cadence Capital Management LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at $263,000. 92.95% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: Investing strategies using the yield curve

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply